Cassava Sciences announced that the phase 3 trial of its Alzheimer’s drug, simufilam, did not meet its primary endpoints.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Controversial Alzheimer's drug trial halted
Cassava Sciences announced that the phase 3 trial of its Alzheimer’s drug, simufilam, did not meet its primary endpoints.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis